Consumer Genomics

Queering the Genome – Are We Ready?

It has been less than a week since the landmark study into the genetics of same-sex sexual behaviour first broke and sparked debate across the twitterverse. There has been much disagreement amongst the scientific and LGBTQ+ communities alike, regarding whether this research should have been conducted at all. Conversely, many have praised the study for […]

Digital DNA: Genetic Counselling – An Interview with Jill Davies

The Digital DNA series explores the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. We talked to Jill Davies, CEO of GeneMatters. The company provides genetic counselling to patients through a telehealth platform […]

Digital DNA: How DNA Testing is Being Used to Cheat the System

The Digital DNA series explores the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. When Ralph Taylor registered his new business, he attempted to declare it as a disadvantaged business enterprise. Businesses headed […]

Illumina’s $1.2 Billion PacBio Takeover Threatened by CMA Concerns

The CMA has announced that Illumina’s $1.2 billion acquisition of Pac Bio is potentially anti-competitive, delaying the expected conclusion of the deal until fourth quarter 2019. The CMA said the deal could remove Illumina’s biggest competitor, leaving limited alternatives available for customers.

Following the Recent Raid, Could uBiome Become Theranos 2.0?

uBiome, a Silicon Valley startup providing tests focussing on the microbiome and its importance to health, is under investigation after an FBI raid on its offices over how it was allegedly billing its customers. The company has received significant criticism recently for handling of the cofounders’ relationship and alleged corner-cutting during its scientific work.

The Rise of Population-scale Genomic Projects for Pharma R&D Investments

Genetic research is a big data problem without researchers generally having access to this “big” genomic and medical data. Not only has it been nearly impossible to access enough relevant data to support research, but analysing the data has been slow and challenging due to its sheer volume. To counter this, in recent years a number of pharmaceutical companies have announced large-scale collaborations around genomic data to uncover novel drug targets, validate existing drug pipelines, predict response, and expand therapeutics use. We discuss some of the biggest and most recent.

An Interview with SOPHiA GENETICS: STS and the CE-IVD Designation

SOPHiA GENETICS’ Solid Tumor Solution (STS) application was recently granted a CE-IVD designation, a regulatory stamp that a product has satisfied the EU’s in vitro diagnostic device requirements. We spoke to Gioia Althoff, SOPHiA’s Senior Vice President, Genomics Business Area, about the STS application and where SOPHiA is going from here.

Amazon Alexa Now HIPAA-Compliant Thanks to Tool Kits

Amazon has announced that new software for its Alexa virtual assistant will allow healthcare companies to build tools which can safely send private information to patients. The announcement was accompanied by the launch of six voice programs created by health companies including Boston Children’s Hospital and digital health company Livongo.